 |
This is a condition, where a patient develops an allergy to the spores of the Aspergillus moulds. Predominantly it affects asthma patients, those with cystic fibrosis (CF) and patients with bronchiectasis. Approximately 1 to 5% of adult asthmatics might develop this at some time during their lives, whereas 5-10% of CF patients may be affected.
Approximately 30% of all asthmatics suffer with severe (20%) or very severe (10%) asthma, and around 30-50% of both these groups are also sensitised to numerous different fungi - these patients have been grouped into a new category called Severe Asthma with Fungal Sensitisation or SAFS -click for more info.
Presentation:
ABPA often presents with shortness of breath, coughing, wheezing and pulmonary infiltrates, which do not respond to conventional antibiotics in asthma/CF sufferers. The symptoms are similar to those of asthma: intermittent episodes of feeling unwell, coughing and wheezing. Some patients cough up brown-coloured plugs of mucus. The diagnosis can be made by X-ray or by sputum, skin or blood tests - an elevated total serum IgE, together with evidence of Aspergillus sensitisation as seen by either the presence Aspergillus antibodies, or identification from respiratory fluid.
In the long term ABPA can lead to permanent lung damage (fibrosis) if left untreated.
Treatment:
Oral long-term, high-dose steroids are the usual method of management. Inhaled steroids are ineffective. Itraconazole (an antifungal drug) has been shown to be of benefit when used in conjunction with steroids and longer term may reduce the dosage of steroids required for ABPA treatment. |